No Data
Research Reports on digging for gold | HAITONG INT'L: Maintain Changchun High-Tech Industries "Outperform Market" rating, focus on the expansion of indications for growth hormone.
On May 16th, GELONGHUI reported that HAITONG INT'L's Research Reports pointed out that Changchun High-Tech Industries (000661.SZ) core subsidiary Jinsai Pharmaceuticals is increasing investment in research and sales, impacting short-term profitability. Attention should be paid to the expansion of indications for growth hormone and the development of new pipelines, maintaining an "outperform market" rating. Currently, on one hand, Jinsai is continuing to expand the indications for growth hormone and accelerating its application in Assisted Reproduction and adult growth hormone deficiency fields. On the other hand, through self-research and business development, a diversified, differentiated, and high-potential innovative pipeline layout is being created to broaden the growth sectors. In terms of research progress, liquid nasal spray influenza vaccine, rabies monoclonal antibody,
CITIC SEC: The implementation difficulty of Trump's EO this time is quite high, with limited short-term impact.
CITIC SEC released a Research Reports stating that on May 12, 2025, Trump signed an executive order titled "Providing Prescription Drug 'Most-Favored-Nation' Pricing to Patients in the USA," aimed at reducing prescription drug prices in the USA market.
Changchun High-Tech Industries (000661) 2024 annual report review: Increased investment in research and sales, performance under pressure during the transition period.
This report introduction: The increased investment in research and development and sales by the core subsidiary JinSai Pharmaceutical affects short-term profitability. It is important to focus on the expansion of indications for growth hormone and the development of new pipelines, maintaining an outperform rating in the market. Investment highlights: Maintaining an outperform rating in the market. Company.
“Manage the company's Market Cap” Changchun High-Tech Industries stock price faced criticism. The company expects the liquid influenza vaccine to be launched this year | Directly reporting from the Earnings Conference.
① During the Earnings Conference, several investors expressed their dissatisfaction with the current stock price of Changchun High-Tech Industries; ② Regarding the competitive landscape that growth hormone may face in the future, Secretary Li Hongyu admitted that the company maintains a rational attitude; ③ The company expects that liquid influenza vaccines, Vaxart's monoclonal antibodies, and other products may be approved for listing this year.
Express News | Overview of A-shares Share Buyback: 21 companies disclosed buyback progress.
Changchun High-Tech Industries (000661.SZ) has repurchased a total of 3.8945 million shares, costing approximately 0.4 billion yuan.
Changchun High-Tech Industries (000661.SZ) announced that as of April 30, 2025, it has cumulatively conducted Trade through centralized bidding...
